Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Catalyst Pharmaceuticals (CPRX) Operating Margin (2018 - 2025)

Historic Operating Margin for Catalyst Pharmaceuticals (CPRX) over the last 11 years, with Q3 2025 value amounting to 44.66%.

  • Catalyst Pharmaceuticals' Operating Margin rose 51000.0% to 44.66% in Q3 2025 from the same period last year, while for Sep 2025 it was 44.76%, marking a year-over-year increase of 69700.0%. This contributed to the annual value of 39.68% for FY2024, which is 178800.0% up from last year.
  • According to the latest figures from Q3 2025, Catalyst Pharmaceuticals' Operating Margin is 44.66%, which was up 51000.0% from 45.24% recorded in Q2 2025.
  • In the past 5 years, Catalyst Pharmaceuticals' Operating Margin registered a high of 53.79% during Q2 2022, and its lowest value of 36.21% during Q3 2023.
  • Moreover, its 5-year median value for Operating Margin was 43.55% (2021), whereas its average is 37.75%.
  • Its Operating Margin has fluctuated over the past 5 years, first crashed by -800700bps in 2023, then surged by 757700bps in 2024.
  • Over the past 5 years, Catalyst Pharmaceuticals' Operating Margin (Quarter) stood at 33.26% in 2021, then surged by 52bps to 50.7% in 2022, then fell by -26bps to 37.71% in 2023, then rose by 18bps to 44.31% in 2024, then rose by 1bps to 44.66% in 2025.
  • Its Operating Margin was 44.66% in Q3 2025, compared to 45.24% in Q2 2025 and 44.81% in Q1 2025.